KR102624473B1 - A Manufacturing method of sliced bellflower sugared - Google Patents
A Manufacturing method of sliced bellflower sugared Download PDFInfo
- Publication number
- KR102624473B1 KR102624473B1 KR1020190093547A KR20190093547A KR102624473B1 KR 102624473 B1 KR102624473 B1 KR 102624473B1 KR 1020190093547 A KR1020190093547 A KR 1020190093547A KR 20190093547 A KR20190093547 A KR 20190093547A KR 102624473 B1 KR102624473 B1 KR 102624473B1
- Authority
- KR
- South Korea
- Prior art keywords
- sugar
- hwangchil
- cheonmundong
- weight
- hours
- Prior art date
Links
- 241000332371 Abutilon x hybridum Species 0.000 title claims abstract description 26
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 11
- 239000000203 mixture Substances 0.000 claims abstract description 17
- 210000002345 respiratory system Anatomy 0.000 claims abstract description 5
- 239000000284 extract Substances 0.000 claims description 56
- 238000000034 method Methods 0.000 claims description 35
- 230000008569 process Effects 0.000 claims description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 7
- 235000006753 Platycodon grandiflorum Nutrition 0.000 claims description 5
- 240000003582 Platycodon grandiflorus Species 0.000 claims description 5
- 235000002789 Panax ginseng Nutrition 0.000 claims description 4
- 235000012907 honey Nutrition 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 238000009461 vacuum packaging Methods 0.000 claims 1
- 239000002131 composite material Substances 0.000 abstract description 4
- 239000000243 solution Substances 0.000 description 21
- 239000000428 dust Substances 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 17
- 239000012530 fluid Substances 0.000 description 14
- 230000002757 inflammatory effect Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 238000002835 absorbance Methods 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 230000000241 respiratory effect Effects 0.000 description 7
- 230000002292 Radical scavenging effect Effects 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 235000020374 simple syrup Nutrition 0.000 description 5
- 101710085496 C-X-C motif chemokine 2 Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 description 4
- 102100038138 WD repeat-containing protein 26 Human genes 0.000 description 4
- 239000000469 ethanolic extract Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 208000023504 respiratory system disease Diseases 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 3
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 101000972282 Homo sapiens Mucin-5AC Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102100022496 Mucin-5AC Human genes 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 description 3
- 235000013824 polyphenols Nutrition 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000009923 sugaring Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- -1 ABTS radical Chemical class 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 108050003558 Interleukin-17 Proteins 0.000 description 2
- 102000013691 Interleukin-17 Human genes 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940124595 oriental medicine Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 235000002568 Capsicum frutescens Nutrition 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NULAJYZBOLVQPQ-UHFFFAOYSA-N N-(1-naphthyl)ethylenediamine Chemical compound C1=CC=C2C(NCCN)=CC=CC2=C1 NULAJYZBOLVQPQ-UHFFFAOYSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 108010030694 avidin-horseradish peroxidase complex Proteins 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical class N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229930189407 platycodin Natural products 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 235000012046 side dish Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- XTQHKBHJIVJGKJ-UHFFFAOYSA-N sulfur monoxide Chemical class S=O XTQHKBHJIVJGKJ-UHFFFAOYSA-N 0.000 description 1
- 229910052815 sulfur oxide Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000021404 traditional food Nutrition 0.000 description 1
- 229930182493 triterpene saponin Natural products 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
- A23L21/10—Marmalades; Jams; Jellies; Other similar fruit or vegetable compositions; Simulated fruit products
- A23L21/12—Marmalades; Jams; Jellies; Other similar fruit or vegetable compositions; Simulated fruit products derived from fruit or vegetable solids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/10—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
- A23L21/20—Products from apiculture, e.g. royal jelly or pollen; Substitutes therefor
- A23L21/25—Honey; Honey substitutes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/314—Foods, ingredients or supplements having a functional effect on health having an effect on lung or respiratory system
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 호흡기 개선에 효과가 있는 도라지 당절편의 제조방법 및 상기 당절편의 제조를 위한 당침액의 복합조성물에 관한 것이다.The present invention relates to a method for producing bellflower sugar segments that are effective in improving the respiratory system and a composite composition of sugar needle solution for producing the sugar segments.
Description
본 발명은 장시간 유지 보관이 가능하면서 호흡기 개선에 효과가 있는 도라지 당절편의 제조방법에 관한 것이다.The present invention relates to a method of manufacturing balloon flower segments that can be stored for a long time and are effective in improving the respiratory system.
현재 미세먼지는 황산화물, 질소산화물, 납, 오존, 일산화탄소 등의 매우 복잡한 성분을 가진 대기 중에서 부유하고 있는 물질이며, 대부분 자동차 배기가스,도로의 먼지 등으로부터 발생하는 것으로 알려져 있다.Currently, fine dust is a substance floating in the atmosphere containing very complex components such as sulfur oxides, nitrogen oxides, lead, ozone, and carbon monoxide, and is known to be mostly generated from automobile exhaust gases and road dust.
미세먼지의 크기와 성분은 매우 복잡하고 다양한데, PM10은 입경 10 mm이하의 미세먼지라 불리고, PM2.5는 입경 2.5 mm이하의 초미세먼지라 불리는데, 입자의 크기, 표면적, 화학적 조성에 따라 건강에 다양하고 많은 영향을 미치게 된다.The size and composition of fine dust are very complex and diverse. PM10 is called fine dust with a particle size of 10 mm or less, and PM2.5 is called ultrafine dust with a particle size of 2.5 mm or less. The health hazard depends on the particle size, surface area, and chemical composition. It has many and varied impacts.
이러한 미세먼지가 호흡기에 미치는 영향은 주로 기관지에서 염증반응을 일으킴으로써 발생하는데, 이러한 작용은 천식, 만성 기관지염, 기도폐쇄 등을 일으키거나 악화시키는 작용을 하게 된다.The impact of fine dust on the respiratory system is mainly caused by causing an inflammatory response in the bronchi, which causes or worsens asthma, chronic bronchitis, and airway obstruction.
또한 미세먼지는 폐 조직에서 박테리아의 불활성화 혹은 제거 작용을 방해함으로써 호흡기계 감염을 일으킬 수도 있으며, 최근에는 미세먼지가 심근경색, 뇌졸증, 심박동수 이상, 급사 등과 같은 심혈관계질환의 중요한 위험요인으로 받아들여지고 있다.In addition, fine dust can cause respiratory infections by interfering with the inactivation or removal of bacteria in lung tissue. Recently, fine dust has become an important risk factor for cardiovascular diseases such as myocardial infarction, stroke, abnormal heart rate, and sudden death. It is being accepted.
따라서 이러한 미세먼지에 일정시간 노출되는 것은 호흡기 및 심혈관계 질환의 발생뿐만 아니라 사망률의 증가와도 관련이 있는 것으로 보고되고 있으며, 연령대별로 보면 신체적으로 면역력이 약한 취학 전 아동과 70대 이상 노인층에서 미세먼지 및 황사의 영향이 더 큰 것으로 나타났다.Therefore, exposure to such fine dust for a certain period of time is reported to be related not only to the occurrence of respiratory and cardiovascular diseases, but also to an increase in mortality. By age group, preschool children and those in their 70s or older, who have physically weak immune systems, are reported to be associated with fine dust exposure. It was found that the impact of dust and yellow dust was greater.
이처럼 최근 미세먼지 등으로 인한 호흡기 건강에 대한 우려가 빠르게 증가함에 따라 공산품, 의약품, 건강기능식품 등 호흡기 건강을 지키기 위한 많은 제품들이 출시되고 있다.As concerns about respiratory health due to fine dust have recently increased rapidly, many products to protect respiratory health, such as industrial products, pharmaceuticals, and health functional foods, are being released.
그러나 국내에서 허가되어 유통중인 건강기능식품 중에는 미세먼지나 황사로 인한 호흡기 질환에 효과가 있거나 이를 예방할 수 있는 기능성이 있는 제품은 없다.However, among the health functional foods approved and distributed in Korea, there are no products that are effective in or have the functionality to prevent respiratory diseases caused by fine dust or yellow dust.
또한 미세먼지가 호흡기 질환을 어떻게 유발하는지에 관한 명확한 기전이 규명되지 않았기 때문에 이와 관련된 바이오의약품 개발은 아직 전무한 실정이다.In addition, because the clear mechanism of how fine dust causes respiratory diseases has not been identified, there has been no development of related biopharmaceuticals yet.
따라서 이를 보완하는 방법으로 미세먼지의 독성을 생체 내에서 저감할 수 있는 기능성 식품연구가 필요하다.Therefore, as a complementary method, research on functional foods that can reduce the toxicity of fine dust in vivo is needed.
이러한 요구에 부응하여 당절편 등 전통 기호성 식품에 민간요법과 한방을 기반으로 한 호흡기 건강에 도움을 주는 식품의 수요가 증가하고 있는데, 특히 한방에서는 도라지를 거담제, 기관지염, 편도선염, 인후염 그리고 다른 호흡기관의 치료목적으로 사용하여 왔다.In response to these demands, the demand for foods that help with respiratory health based on folk remedies and oriental medicine is increasing in addition to traditional food items such as dangjeolpyeon. In particular, in oriental medicine, bellflower root is used as an expectorant, bronchitis, tonsillitis, sore throat, and other respiratory diseases. It has been used for treatment purposes.
또한 도라지는 Triterpene saponins, inulin, sterol 등의 구성성분이 약리효과를 나타내고 천연 그대로의 platycodin이 주 약리효능의 성분으로 보고되고 있고, 식품으로서의 도라지는 천식, 폐결핵, 고혈압, 당뇨병, 염증 등의 성인병과 진정제 및 진통제의 사용을 위하여 민간요법 목적으로 재배되어 단순한 반찬으로 섭취하거나, 도라지 단독 혹은 배 등과 혼합하여 착즙한 제품이 대부분이다.In addition, bellflower root components such as triterpene saponins, inulin, and sterol exhibit pharmacological effects, and natural platycodin is reported to be the main pharmacological ingredient. Bellflower root as a food is effective in treating adult diseases such as asthma, pulmonary tuberculosis, hypertension, diabetes, and inflammation. Most of the products are grown for folk remedies to be used as sedatives and painkillers and consumed as a simple side dish, or extracted from bellflower root alone or mixed with pears.
그러나 이러한 것들은 손쉽게 취식이 어렵다는 것이다.However, these things are difficult to consume easily.
따라서 최근 최식이 용이토록 도라지 당절임이 출시되었으나 호흡기 개선 효과는 검증되지 않았다.Therefore, sugar-pickled bellflower root was recently released to make it easier to eat, but its effect on improving respiratory system has not been verified.
따라서 본 발명은 도라지를 주 원료로 하고, 호흡기 건강에 효과가 있다고 보고된 천문동과 황칠 추출 농축액 복합조성물로 당침액을 조제하여 호흡기 개선 효과를 규명하여 기호성 뿐만 아니라 호흡기 건강 기능성을 부가하고자 한다.Therefore, the present invention uses bellflower root as the main raw material and prepares a sugar needle solution with a complex composition of Cheonmundong and yellow chili extract concentrate, which has been reported to be effective in respiratory health, to identify the respiratory improvement effect and add respiratory health functionality as well as palatability.
이를 위하여 잘게 세절하여 건조된 천문동과 황칠을 중량대비 10배의 50%에탄올에 70℃에서 24시간 3회 반복 각각 추출하여, 여과 농축하고, 동결건조한 추출물을 천문동과 황칠을 중량대비 5:5 비율로 혼합하고, 여기에 홍삼 추출물(10중량%), 꿀(30중량%), 그리고 5:5비율로 배합된 황칠+천문동 추출물 배합(60중량%)으로 혼합하여 당침액 원액을 제조하였다.For this purpose, finely chopped and dried Cheonmundong and Hwangchil were extracted with 10 times the weight of 50% ethanol at 70°C three times for 24 hours, filtered and concentrated, and the freeze-dried extract was mixed with Cheonmundong and Hwangchil in a 5:5 ratio by weight. and mixed with red ginseng extract (10% by weight), honey (30% by weight), and Hwangchil + Cheonmundong extract blended in a 5:5 ratio (60% by weight) to prepare a sugar needle solution.
상기 당침액 원액과 물(멸균수)을 1:1 비율로 혼합하여 최종 당침액을 제조한 후 최종 당침액과 건조 도라지 절편을 2:1 비율로 혼합한 다음, 건조 도라지 절편을 최종 당침액에 충분히 침지시켰다.The final sugar steeping solution was prepared by mixing the sugar steeping solution and water (sterilized water) in a 1:1 ratio, then the final sugar steeping solution and dried bellflower slices were mixed in a 2:1 ratio, and then the dried bellflower slices were added to the final sugar steeping liquid. It was sufficiently immersed.
침지 후에는 70℃에서 6시간 가열하여 1차 당침, 1차 당침 후 12시간 실온 숙성, 숙성 후 70℃ 온도로 6시간 가열하여 2차 당침을 진행하였다.After immersion, the first sugar needle was heated at 70°C for 6 hours, the first sugar needle was aged at room temperature for 12 hours, and then the second sugar needle was heated at 70°C for 6 hours after aging.
당침 과정이 끝나면 실온에서 6시간 동안 건조 및 도라지에 묻어 있는 당침액을 자연스럽게 흘려서 제거시킨 후 45℃ 온도에서 24시간 건조시켰으며, 건조 후 12% 이하의 수분함량을 확인 후 진공 포장한 것이다.After the sugar needle process was completed, it was dried at room temperature for 6 hours, and the sugar needle liquid on the bellflower was naturally drained to remove it, then dried at 45°C for 24 hours. After drying, the moisture content was confirmed to be less than 12% and then vacuum-packed.
따라서 기관지 및 폐 염증억제 활성이 높게 나타났으며 특히 천문동과 황칠을 5:5 비율로 혼합하였을 때 가장 높은 염증 억제 활성을 나타내었다.Therefore, the bronchial and lung inflammation inhibition activity was high, and especially when Cheonmundong and Hwangchil were mixed in a 5:5 ratio, the highest inflammation inhibition activity was shown.
도1은 본 발명의 제조공정을 도시한 블럭도.1 is a block diagram showing the manufacturing process of the present invention.
이하 일실시예에 의거 본 발명을 상세히 설명하면 다음과 같다.Hereinafter, the present invention will be described in detail based on an embodiment as follows.
도1에 도시된 바와 같이 본 발명의 제조방법은 다음의 공정순서로 이루어진다.
제1공정으로서, 건조된 천문동과 황칠을 각각 잘게 세절하여 얻어진 것을 중량대비 10배의 50% 에탄올에 70℃에서 24시간 3회 반복추출하여, 여과 농축하고, 동결건조한, 각각의 천문동과 황칠을 분말상의 추출물로 얻는 공정이다.As shown in Figure 1, the manufacturing method of the present invention consists of the following process sequence.
In the first step, the dried Cheonmundong and Hwangchil were finely chopped and extracted with 10 times the weight of 50% ethanol at 70°C three times for 24 hours, filtered, concentrated, and freeze-dried. This is a process to obtain a powdered extract.
제2공정으로는, 제1공정에서 얻어진 각각의 분말상의 추출물을 천문동과 황칠을 중량대비하여 5:5 비율로 혼합하여 황칠+천문동 추출물의 분말상의 혼합물 60중량%와 분말상의 홍삼 추출물 10중량%, 겔상의 꿀 30중량%로 혼합하여 당침액 원액 즉 복합조성물을 제조하는 공정이다.In the second process, each powdered extract obtained in the first process was mixed with Cheonmundong and Hwangchil in a 5:5 ratio by weight to obtain 60% by weight of the powdered mixture of Hwangchil + Cheonmundong extract and 10% by weight of powdered red ginseng extract. This is a process of producing a sugar needle solution, that is, a composite composition, by mixing 30% by weight of gel-like honey.
제3공정으로는 상기 제2공정에서 얻어진 당침액 원액(복합조성물)과 물(멸균수)을 1:1 비율로 혼합하여 최종 당침액을 제조하는 공정이다.The third process is a process of preparing the final sugar needle solution by mixing the sugar needle solution (composite composition) obtained in the second process and water (sterilized water) in a 1:1 ratio.
제4공정으로는. 상기 제3공정에서 얻어진 최종 당침액과 건조 도라지 절편을 부피대비 2:1 비율로 혼합한 다음, 건조 도라지 절편을 최종 당침액에 충분히 침지시키는 공정이다.
본 발명에서 충분히 침지시킨다는 의미는 건조된 도라지 절편이 최종당침액에서 부유되지 않토록 한 상태에서 일정시간동안 침지토록 하여 건조된 도자지 절편에 최종당침액이 충분하게 침투되도록 한다는 의미이다.As for the 4th process. This is a process of mixing the final sugar-impregnated liquid obtained in the third process and dried bellflower slices in a 2:1 ratio by volume, and then sufficiently immersing the dried bellflower slices in the final sugar-impregnated liquid.
In the present invention, sufficiently immersing means soaking the dried bellflower slices for a certain period of time while preventing them from floating in the final sugar soaking liquid so that the dried bellflower slices are sufficiently penetrated with the final sugar soaking liquid.
제5공정으로는,상기 제4공정에서 충분히 침지된 상태에서 70℃에서 6시간 가열하여 1차 당침하는 공정이다.
이는 일정온도상에서 건조된 도라지가 팽창되면서 최종 당침액도 가온된 상태에서 침투를 균일하게 유지하기 위한 것이다.
제6공정으로는, 상기 제5공정에 의하여 1차 당침 후 12시간 실온에서 당침된 상태에서 숙성하는 공정이다.
이때에도 가능하면 부유되지 않은 상태로 유지하는 것이 좋다
제7공정으로는, 상기 제6공정에서 숙성된 것을 70℃ 온도로 6시간 가열하여 2차 당침을 하는 공정이다.
이는 최종 당침액이 건조된 도라지에 균일한 농도록 당침이 이루어지도록 하기 위한 것이다.The fifth process is a process of first sugaring by heating at 70°C for 6 hours in a state that has been sufficiently immersed in the fourth process.
This is to maintain uniform penetration while the final saccharide solution is also warmed as bellflower root dried at a certain temperature expands.
The sixth process is a process of maturing in the sugared state at room temperature for 12 hours after the first sugaring according to the fifth process.
Even at this time, it is best to keep it in a non-floating state if possible.
In the 7th process, the product aged in the 6th process is heated to a temperature of 70°C for 6 hours to perform secondary sugaring.
This is to ensure that the final sugar solution is sugared to a uniform consistency on the dried balloon flower.
제8공정으로는, 상기의 공정에 의하여 당침 과정이 끝나면 실온에서 6시간 동안 건조 및 도라지에 묻어 있는 당침액을 자연스럽게 흘려서 제거시킨 후 45℃ 온도에서 24시간 건조시키는 공정이다.
제9공정으로는, 상기 제8공정에 의하여 건조된 것을 12% 이하의 수분함량으로 유지되어 있는지의 여부를 확인하여 진공 포장하는 공정으로 제조되는 것이다.The 8th process is a process of drying at room temperature for 6 hours after the sugar needle process is completed by the above process, removing the sugar needle liquid on the bellflower root by naturally flowing it, and then drying it at 45°C for 24 hours.
In the 9th process, the product dried in the 8th process is vacuum-packed after checking whether the moisture content is maintained at 12% or less.
다음은 이러한 각각의 공정에 의하여 얻어지는 과장에 대한 실험결과이다.The following are the experimental results of exaggeration obtained by each of these processes.
제1공정에 의하여 건조된 천문동과 황칠을 잘게 세절하여 원료 중량 대비 10배의 50% 에탄올을 더한 다음 70℃에서 24시간, 3회 반복 추출하여 원심분리 후 여과하여 얻어진 여과액을 농축한 다음 동결 건조하여 천문동 및 황칠 분말상의 추출물을 제조하였다.Finely chop the Cheonmundong and Hwangchil dried in the first process, add 50% ethanol 10 times the weight of the raw material, extract three times for 24 hours at 70℃, centrifuge, filter, concentrate the filtrate, and then freeze. By drying, extracts of Cheonmundong and Hwangchil powder were prepared.
이후 총 폴리페놀 함량확인을 위하여 각각의 추출물 1㎖에 각각 증류수 10㎖를 첨가한 후, 2㎖의 Folin-Ciocalteu phenol reagent를 첨가하여 혼합한 다음, 실온에서 5분간 반응하였다. Afterwards, to check the total polyphenol content, 10 ml of distilled water was added to 1 ml of each extract, then 2 ml of Folin-Ciocalteu phenol reagent was added, mixed, and reacted at room temperature for 5 minutes.
삭제delete
이 반응물에 20% 소듐카보네이트를 2㎖ 첨가하여 혼합한 다음, 상온에서 1시간 반응시킨 후 725nm에서 흡광도를 측정하였다. 2 mL of 20% sodium carbonate was added to the reaction mixture, mixed, reacted at room temperature for 1 hour, and absorbance was measured at 725 nm.
이때 지표물질은 탄닌산(tannic acid)을 사용하였다.At this time, tannic acid was used as an indicator substance.
이후 항산화 활성을 위하여 Yoshida 등(1989)이 사용한 방법을 약간 변형하여 1,1-diphenyl-2-picrylhydrazyl (DPPH) 라디칼에 대한 소거 효과를 측정하였다.Afterwards, for antioxidant activity, the method used by Yoshida et al. (1989) was slightly modified to measure the scavenging effect on 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical.
삭제delete
DPPH 라디컬소거능은 추출물 0.5mL (10.0μ에 0.2mM 2,2-diphenyl-2-picrylhydrazl (DPPH) 용액을 0.5mL 분주하여 30분간 방치시킨 후, 517 nm에서 흡광도(GENESYS 10 UV)를 측정하였다. DPPH radical scavenging ability was measured by dispensing 0.2mM 2,2-diphenyl-2-picrylhydrazl (DPPH) solution into 0.5mL (10.0μ) of the extract, leaving it for 30 minutes, and measuring the absorbance (GENESYS 10 UV) at 517 nm. .
대조군은 시료 대신 용매를 가하여 동일한 방법으로 측정하였다. The control group was measured in the same way by adding a solvent instead of the sample.
양성대조군은 Vitamin C를 10.0 μ로 준비하여 시험하였다. The positive control group was tested with 10.0 μL of Vitamin C.
또한 시료 자체의 색에 대한 흡광도 값을 보정하기 위해 0.2 nm DPPH 대신에 메탄올을 첨가하여 흡광도를 측정하였다. Additionally, to correct the absorbance value for the color of the sample itself, methanol was added instead of 0.2 nm DPPH and the absorbance was measured.
이때 얻어진 값을 기준으로 추출물의 항산화 활성을 백분율로 표시하였고, 환산한 값이 100%에 가까울수록 항산화 활성이 높은 것으로 표현하였다.At this time, the antioxidant activity of the extract was expressed as a percentage based on the obtained value, and the closer the converted value was to 100%, the higher the antioxidant activity was expressed.
ABTS 라디컬 소거 활성을 측정하기 위하여 Roberta 등의 방법을 변형하여 이용하였다. To measure ABTS radical scavenging activity, a modified method of Roberta et al. was used.
ABTS 라디컬 용액의 제조는 증류수에 7mM ABTS와 2.45mM 황산칼륨을 첨가하여 상온에서 16시간 동안 ABTS 양이온을 생산시켰다. To prepare the ABTS radical solution, 7mM ABTS and 2.45mM potassium sulfate were added to distilled water to produce ABTS cations for 16 hours at room temperature.
이때 734nm에서 흡광도의 값이 0.7 이하가 되도록 희석하여 제조하였다.At this time, it was diluted and prepared so that the absorbance value at 734 nm was 0.7 or less.
ABTS 용액 950ul에 각 농도별 시료 50ul를 첨가하여 10분동안 반응시킨 후, 734nm에서 흡광도를 측정하였다. 50ul of the sample at each concentration was added to 950ul of the ABTS solution and reacted for 10 minutes, and then the absorbance was measured at 734nm.
양성 대조군으로서는 실시예의 물질 대신 BHA를 사용하였다. As a positive control, BHA was used instead of the material in the examples.
각 시료의 자유 라디칼 소거 효과는 라디칼을 50% 소거하는 농도를 구하여 SC50으로 표시하였다. The free radical scavenging effect of each sample was expressed as SC 50 by calculating the concentration that scavenges 50% of the radicals.
이때 음성 대조군으로는 시료를 처리하지 않은 액의 반응 흡광도로 하였다.At this time, the negative control was the absorbance response of the solution without any sample treatment.
세포배양을 위하여 천문동과 황칠 분말상의 추출물에 의한 세포 생존율 변화를 알아보기 위해 MH-S 폐대식세포 (ATCC, CRL 2019)를 10% FBS가 포함된 RPMI 1640 배지에서 배양한 후 세포가 90~100%로 배양 되었을 때 계대하여 사용하였다.For cell culture, to determine changes in cell viability by extracts of Cheonmun-dong and Hwangchil powder, MH-S lung macrophages (ATCC, CRL 2019) were cultured in RPMI 1640 medium containing 10% FBS, and then the cells were 90-100% dead. When cultured, it was passaged and used.
삭제delete
또한 분말상의 천문동과 황칠의 LPS 및 미세먼지에 의한 세포 생존율과 NO분석 복합조성물의 폐대식세포에 대한 사멸효과를 MTT assay를 사용하여 시험하였다. In addition, the cell survival rate caused by LPS and fine dust of powdered Cheonmundong and Hwangchil and the killing effect of NO analysis complex composition on lung macrophages were tested using MTT assay.
MH-S 세포를 1×105cells/well의 밀도로 10% 소태아혈청(Fetal bovine serum, FBS; Gibco), 100 units/ml 페니실린 및 100 ug/ml 스트렙토마이신을 함유한 RPMI1640 배지가 담긴 96웰 배양플레이트에서 37°C, 5% CO2환경으로 1일 배양한 후 혈청이 첨가되지 않은 RPMI1640 배지로 교체하고, 복합조성물을 농도별로 첨가하여 24시간 배양하였다. MH-S cells were grown at a density of 1×10 5 cells/well in RPMI1640 medium containing 10% fetal bovine serum (FBS; Gibco), 100 units/ml penicillin, and 100 ug/ml streptomycin. After culturing in a well culture plate at 37°C in a 5% CO 2 environment for 1 day, the medium was replaced with RPMI1640 medium without serum, and complex compositions were added at different concentrations and cultured for 24 hours.
MTT 용액(5mg/ml; Sigma, 미국)을 웰당 20ul씩 첨가하여 37°C에서 4시간 반응 후 MTT 용액을 제거하고 DMSO를 웰당 100ul씩 첨가하였다. 20ul of MTT solution (5mg/ml; Sigma, USA) was added per well, and after reaction at 37°C for 4 hours, the MTT solution was removed, and 100ul of DMSO was added per well.
실온에서 포르마잔 유도체를 녹인 후 490nm에서 흡광도를 측정하였다.After dissolving the formazan derivative at room temperature, the absorbance was measured at 490 nm.
NO생성은 상등액을 취하여 Griess reagent (0.2% N-(1-naphthyl)ethylene diamine 용액: 0.2% sulfanilamide 용액=1:1)를 이용, 540 nm에서 흡광도를 측정하였다. For NO production, the supernatant was taken and the absorbance was measured at 540 nm using Griess reagent (0.2% N-(1-naphthyl)ethylene diamine solution: 0.2% sulfanilamide solution=1:1).
NO 생성 저해 활성은 LPS 만을 처리한 군과 비교하는 방법으로 평가하였다.The NO production inhibitory activity was evaluated by comparing with the group treated with LPS only.
또한 천문동과 황칠 추출물의 PM에 의한 항염증 효과 및 최적 조성비를 얻기 위하여 MH-S 폐 대식세포 배양 후, 천문동과 황칠 추출물을 0 ~ 100 ug/ml 농도로 혼합처리 한 다음, PM으로 24시간 동안 염증반응을 유도하였다. In addition, in order to obtain the anti-inflammatory effect and optimal composition ratio of Cheonmundong and Hwangchil extracts by PM, after culturing MH-S lung macrophages, Cheonmundong and Hwangchil extracts were mixed at a concentration of 0 to 100 ug/ml, and then treated with PM for 24 hours. An inflammatory response was induced.
삭제delete
24시간 후,세포생존율과 NO 생성량을 측정하여 당침액 레시피 개발을 위한 최적 조성비를 확립하였다.After 24 hours, cell survival rate and NO production were measured to establish the optimal composition ratio for developing the sugar syrup recipe.
또한 당침액 레시피 확립 및 동물실험을 위한 도라지 당절임 샘플 제조를 위하여 최적 복합조성비를 기반으로 최적의 도라지 당침액을 제조하기 위하여 50Brix 천문동과 황칠 추출물을 제조하였다.In addition, 50Brix Cheonmundong and Hwangchil extracts were prepared to prepare the optimal bellflower syrup based on the optimal composite composition ratio in order to establish a sugar syrup recipe and prepare sugar-pickled bellflower root samples for animal testing.
삭제delete
천문동과 황칠 추출물 함량을 각각 다르게 하여(천문동 추출물:황칠 추출물=7:3, 5:5, 3:7, 10:0) 4종의 당침액 원액을 제조한 다음, 홍삼 추출물(10중량%), 꿀(30중량%), 황칠+천문동 추출물 배합(60중량%)으로 혼합하였다.Four types of sugar needle solution were prepared by varying the contents of Cheonmundong and Hwangchil extract (Cheonmundong extract:Hwangchil extract = 7:3, 5:5, 3:7, 10:0), and then adding red ginseng extract (10% by weight). , honey (30% by weight), and Hwangchil + Cheonmundong extract mixture (60% by weight).
상기 4종 당침액 원액과 물(멸균수)을 1:1 비율로 혼합하여 최종 당침액을 제조한 후 당침액과 건조 도라지 절편을 부피대비 2:1 비율로 혼합한 다음, 건조 도라지 절편을 충분히 침지시켰다.The final sugar syrup was prepared by mixing the four types of sugar syrup and water (sterilized water) in a ratio of 1:1, then mixing the sugar syrup and dried bellflower slices in a ratio of 2:1 by volume, and then thoroughly sacrificing the dried bellflower slices. immersed.
침지 후에는 70℃에서 6시간 가열하여 1차 당침, 1차 당침 후 12시간 실온 숙성, 숙성 후 70℃ 온도로 6시간 가열하여 2차 당침을 진행하였다.After immersion, the first sugar needle was heated at 70°C for 6 hours, the first sugar needle was aged at room temperature for 12 hours, and then the second sugar needle was heated at 70°C for 6 hours after aging.
당침 과정이 끝나면 실온에서 6시간 동안 건조 및 도라지에 묻어 있는 당침액을 자연스럽게 흘려서 제거시킨 후 45℃ 온도에서 24시간 건조시켰으며, 건조 후 12% 이하의 수분함량을 확인 후 진공 포장하여 보관 및 동물실험에 사용하였다.After the sugar needle process was completed, it was dried at room temperature for 6 hours, and the sugar needle liquid on the balloon flower was naturally drained and removed, then dried at 45°C for 24 hours. After drying, the moisture content was confirmed to be less than 12%, and then vacuum-packed for storage and animal use. It was used in the experiment.
또한 총 기관지 폐포세척액(BAL :bronchoalveolar lavage) 세포수 측정을 위하여 Balb/c 수컷 마우스를 각 군당 6마리로 하여 정상군을 제외한 모든 군에 PM을 기도로 흡입시키는 방법을 이용하여 14일간 매일 하루에 2번 주입하였다.In addition, to measure the total number of bronchoalveolar lavage (BAL) cells, six Balb/c male mice were selected per group, and all groups except the normal group were treated with PM inhaled into the airway every day for 14 days. Injected twice.
삭제delete
그리고 천문동과 황칠 비율을 달리한 추출물을 500 mg/Kg으로 하루에 한번 급이시켰다.And extracts with different ratios of Cheonmundong and Hwangchil were fed at 500 mg/Kg once a day.
삭제delete
실험 종료 후,부검을 진행하여 BAL fluid을 회수하였다. After completion of the experiment, an autopsy was performed and BAL fluid was recovered.
또한 폐 조직 내 염증인자 mRNA 발현 수준 측정을 위하여 적출한 폐 조직에 Easy-Blue 시약(Intron Biotechnology Inc.)을 이용하여 총 RNA를 분리하였다. In addition, to measure the expression level of inflammatory factor mRNA in lung tissue, total RNA was isolated from the extracted lung tissue using Easy-Blue reagent (Intron Biotechnology Inc.).
삭제delete
총 RNA는 NANO drop 1000 spectrophotometer system(Thermo)을 이용하여 정량화하고, 역전사(reverse transcription)를 수행하여 cDNA를 합성하였다. Total RNA was quantified using the NANO drop 1000 spectrophotometer system (Thermo), and reverse transcription was performed to synthesize cDNA.
구체적으로 50mM Tris-HCl(pH 8.3), 75mM KCl, 3mM MgCl2, 10mM DTT (Invitrogen), 1U/ulRNasin(Invitrogen), 1mM each dNTP, oligo(dT)20 100ng과 MMLV reverse transcriptase(Invitrogen) 200U가 함유된 20ul의 용액에서 총 RNA 1ug으로부터 합성하였다. Specifically, it contains 50mM Tris-HCl (pH 8.3), 75mM KCl, 3mM MgCl2, 10mM DTT (Invitrogen), 1U/ulRNasin (Invitrogen), 1mM each dNTP, 100ng of oligo(dT)20 and 200U of MMLV reverse transcriptase (Invitrogen). It was synthesized from 1ug of total RNA in 20ul of solution.
합성된 cDNA의 전사체는 SYBR green master mix (Applied Biosystems, 미국) 및 하기 <표 7>의 프라이머(primer)를 이용하여 StepOnePlus Real-time PCR system(Applied Biosystems)을 통해 정량적 실시간 PCR을 수행하였다. Quantitative real-time PCR was performed on the synthesized cDNA transcript using the StepOnePlus Real-time PCR system (Applied Biosystems) using SYBR green master mix (Applied Biosystems, USA) and the primers shown in <Table 7> below.
각 시료의 표준화를 위해 GAPDH를 사용하였다. GAPDH was used for standardization of each sample.
각 시료의 표준화를 위해 GAPDH를 사용하였다.GAPDH was used for standardization of each sample.
<RT-PCR사용 프라이머><Primers used for RT-PCR>
또한 기관지 폐포세척액(BAL fluid)내 염증인자 발현 측정을 위하여 기관지폐포세척액(BAL fluid)에서 TNF-a, MIP2, RMFLRH CXCL-1 수준을 ELISA로 측정하였다. In addition, to measure the expression of inflammatory factors in BAL fluid, the levels of TNF-a, MIP2, and RMFLRH CXCL-1 in BAL fluid were measured by ELISA.
삭제delete
TNF-a항체 (MTA00B, R&D systems, Minneapolis, USA), MIP2 항체 (MM200, R&D systems, Minneapolis, USA), CXCL-1 항체 (MKC00B, R&D systems, Minneapolis, USA)를 완충용액으로 희석하여 96웰이 코팅한 후에 4°C에서 16시간 배양하였다.TNF-a antibody (MTA00B, R&D systems, Minneapolis, USA), MIP2 antibody (MM200, R&D systems, Minneapolis, USA), and CXCL-1 antibody (MKC00B, R&D systems, Minneapolis, USA) were diluted with buffer solution and used in 96 wells. After coating, the cells were incubated at 4°C for 16 hours.
각 웰을 완충용액으로 3회 세척한 후에 10배 희석한 혈청을 100mL씩 분주하였다.After washing each well three times with a buffer solution, 100 mL of 10-fold diluted serum was dispensed.
한 시간 동안 실온에서 방치한 후 2회 세척하고 Avidin-HRP가 결합된 항체 (DY007, R&D systems, Minneapolis, USA)를 100mL씩 처리하고 1시간동안 실온에서 방치한 후 다시 세척하였다.After being left at room temperature for one hour, washed twice, treated with 100 mL of Avidin-HRP-conjugated antibody (DY007, R&D systems, Minneapolis, USA), left at room temperature for 1 hour, and washed again.
TMB 기질 (DY007, R&D systems, Minneapolis, USA)을 100mL씩 분주하고 암소에서 30분간 방치한 후 50mL stop 용액 (DY007, R&D systems, Minneapolis, USA)을 처리한 후 450nm에서 흡광도를 측정하였다.100 mL of TMB substrate (DY007, R&D systems, Minneapolis, USA) was dispensed, left in the dark for 30 minutes, treated with 50 mL stop solution (DY007, R&D systems, Minneapolis, USA), and absorbance was measured at 450 nm.
상기에 의한 실험결과 는 다음과 같다.The results of the above experiment are as follows.
1. 용매에 따른 추출물의 함량 변화1. Change in extract content depending on solvent
물과 50% 에탄올을 사용하여 50°C에서 추출하여 동결건조 후 추출물의 yield을 측정한 결과, 50% 에탄올에서 함량이 약 50~55% 가량 더 증가하는 것으로 나타났다.As a result of measuring the yield of the extract after extraction at 50°C using water and 50% ethanol and freeze-drying, it was found that the content increased by about 50 to 55% in 50% ethanol.
뿐만 아니라, 총 폴리페놀의 함량 또한 물 추출물에 비해 에탄올 추출물에서 유의적으로 높게 나타났기 때문에 50% 에탄올 추출물을 시료로 사용하였다.In addition, the total polyphenol content was also found to be significantly higher in the ethanol extract than in the water extract, so a 50% ethanol extract was used as the sample.
삭제delete
2. 항산화 분석 2. Antioxidant analysis
50% 에탄올을 용매로 추출한 천문동과 황칠 분말상의 추출물의 항산화 활성을 DPPH 및 ABTS 라디컬 소거능으로 측정하였다.The antioxidant activity of Cheonmundong and Hwangchil powder extracts extracted with 50% ethanol as a solvent was measured using DPPH and ABTS radical scavenging activities.
다른 천연물 유래 추출물과 유사한 범위에서 DPPH 및 ABTS 라디컬 소거능이 확인되었는데, DPPH 라디컬 소거능은 천문동 추출물이 황칠 추출물에 비해 약 1.6배 높은 65.4 (SC50)로 나타났으며, ABTS 라디컬 소거능은 황칠 추출물이 천문동 추출물에 비해 3.4배 높은 9.35 (SC50)로 나타났다.The DPPH and ABTS radical scavenging ability was confirmed in a similar range to that of extracts derived from other natural products. The DPPH radical scavenging ability of the Cheonmundong extract was found to be 65.4 (SC50), which is about 1.6 times higher than that of the Hwangchil extract, and the ABTS radical scavenging ability was found to be 65.4 (SC50), which is about 1.6 times higher than that of the Hwangchil extract. It was found to be 9.35 (SC50), which is 3.4 times higher than the Cheonmundong extract.
3. 천문동 추출물과 황칠 추출물의 미세먼지에 대한 항염증 효과 3. Anti-inflammatory effect of Cheonmundong extract and Hwangchil extract against fine dust
천문동과 황칠 추출물을 MH-S 폐대식세포에 0~100 ug/ml 농도로 혼합처리하고, LPS 처리한 다음 세포생존율과 NO 생성량을 확인한 결과, 각각 단독처리에 비해 천문동과 황칠 추출물을 각각 50 ug/ml씩 혹은 천문동30 ug/ml과 황칠70 ug/ml 농도로 혼합처리 하였을 때 LPS에 의해 감소된 세포생존율은 증가시켰으며, 증가된 NO 생성량은 감소시켰다 (그림 1).Cheonmundong and Hwangchil extracts were mixed with MH-S lung macrophages at a concentration of 0 to 100 ug/ml, treated with LPS, and the cell viability and NO production were checked. As a result, compared to treatment alone, 50 ug/ml of Cheonmundong and Hwangchil extracts were used. When treated ml at a time or mixed at a concentration of 30 ug/ml Cheonmundong and 70 ug/ml Hwangchil, the cell survival rate reduced by LPS was increased and the increased NO production was reduced (Figure 1).
즉,천문동과 황칠 추출물을 5 : 5 혹은 3 : 7 비율로 혼합하였을 때 단독 처리에 비해 항염증 효과가 유의적으로 높게 나타났다.In other words, when Cheonmundong and Hwangchil extracts were mixed in a ratio of 5:5 or 3:7, the anti-inflammatory effect was significantly higher than when treated alone.
이 결과는 LPS대신 PM을 처리하였을 때에도 동일하게 나타났다 (그림 2). This result was the same even when PM was treated instead of LPS (Figure 2).
< 그림 1 >천문동과 황칠 추출물 혼합처리의 LPS에 의한 항염증 효과< Figure 1 > Anti-inflammatory effect of LPS in mixed treatment of Cheonmundong and Hwangchil extracts
< 그림 2 >천문동과황칠 추출물 혼합처리의PM에 의한 항염증 효과< Figure 2 > Anti-inflammatory effect of PM from mixed treatment of Cheonmundong and Hwangchil extracts
4. 총 기관지폐포세척액(BAL) 세포수 측정4. Total bronchoalveolar lavage fluid (BAL) cell count measurement
총 기관지 폐포세척액 세포수에 미치는 영향은 하기 문헌에 기재된 방법을 응용하여 실험하였다. The effect on the total number of bronchoalveolar lavage fluid cells was tested using the method described in the following literature.
(Schines et al., ToxicolApplPharmacol. 195(1), 1-11 (2004)와 Smith et al.,ToxicolSci, 93(2), 390-399 (2006)) 각 시료들에 대한 총 기관지 폐포 세척액세포수에 미치는 영향을 측정한 결과를 표 4에 나타내었다.(Schines et al., Toxicol Appl Pharmacol. 195(1), 1-11 (2004) and Smith et al., Toxicol Sci, 93(2), 390-399 (2006)) Total bronchoalveolar lavage fluid cell count for each sample The results of measuring the impact are shown in Table 4.
총 BAL 세포수는유발군에 비해 감소하여 시료 모두 염증 수치 감소에 기여하는 것을 확인하였으며, 특히 천문동과 황칠 추출물을 5 : 5 비율로 혼합한 시료에서 가장 낮은 기관지 염증 억제활성을 나타내었다.The total number of BAL cells decreased compared to the induced group, confirming that all samples contributed to the reduction of inflammation levels. In particular, the sample mixed with Cheonmundong and Hwangchil extracts in a 5:5 ratio showed the lowest bronchial inflammation inhibitory activity.
(´105cell/ml)Total BAL cells
(´10 5 cells/ml)
(유발군 기준)inhibition rate
(Based on trigger group)
5. 폐내 염증인자mRNA 발현에 미치는 영향 5. Effect on inflammatory factor mRNA expression in the lungs
표 5는 폐내 염증인자mRNA 발현에 미치는 영향을 나타낸 것이다.Table 5 shows the effect on inflammatory factor mRNA expression in the lung.
각 시료 투여군들의 염증인자(MUC5AC, CCR5)는 유발군에 비해 감소하였으며,총기관지 폐포세척액 세포수 결과와 동일하게 천문동과 황칠 추출물을 5 : 5 비율로 혼합한 시료에서 가장 높은 염증인자 억제율을 나타내었다.Inflammatory factors (MUC5AC, CCR5) in each sample administration group decreased compared to the induced group, and, consistent with the total bronchoalveolar lavage fluid cell count results, the highest inflammatory factor inhibition rate was shown in the sample mixed with Cheonmundong and Hwangchil extract in a 5:5 ratio. It was.
(유발군 기준)inhibition rate
(Based on trigger group)
(유발군 기준)inhibition rate
(Based on trigger group)
6. 기관지 폐포세척액 내 염증인자 발현 측정 6. Measurement of inflammatory factor expression in bronchoalveolar lavage fluid
각 시료에 대한 기관지 폐포세척액 내 염증인자 발현 수준에 미치는 영향을 확인하기 위해 하기와 같은 문헌에 기재된 방법을 응용하여 실험하였다(Brandt EB et al., J. Allergy Clin. Immunol. 135(5): 1194-1204 (2013)). To determine the effect on the expression level of inflammatory factors in bronchoalveolar lavage fluid for each sample, an experiment was performed using the method described in the literature as follows (Brandt EB et al., J. Allergy Clin. Immunol. 135(5): 1194-1204 (2013)).
표 6은 기관지 폐포세척액 내 IL-17A, TNF-a, 그리고 MIP2와 같은 염증인자 발현을 측정한 결과를 나타낸 것이다.Table 6 shows the results of measuring the expression of inflammatory factors such as IL-17A, TNF-a, and MIP2 in bronchoalveolar lavage fluid.
각 시료 투여군들의 염증인자는 유발군에 비해 모두 감소되었다.Inflammatory factors in each sample administration group were all reduced compared to the induced group.
앞서 나타난 결과와 동일하게 기관지 폐포세척액 내 염증인자 발현 억제율 또한 천문동과 황칠 추출물을 5 : 5 비율로 혼합한 시료에서 가장 높게 나타냄을 확인하였다.Consistent with the previous results, it was confirmed that the inhibition rate of inflammatory factor expression in bronchoalveolar lavage fluid was highest in samples mixed with Cheonmundong and Hwangchil extracts in a 5:5 ratio.
즉, 단일 추출물에 비해 천문동과 황칠 혼합물을 당침액으로 사용하였을 때 기관지 및 폐 염증억제 활성이 높게 나타났으며 특히 천문동과 황칠을5 : 5 비율로 혼합하였을 때 가장 높은 염증 억제 활성을 나타내었다.In other words, compared to the single extract, when the mixture of Cheonmundong and Hwangchil was used as a sugar needle solution, the bronchial and lung inflammation inhibition activity was higher. In particular, when Cheonmundong and Hwangchil were mixed at a ratio of 5:5, the highest anti-inflammatory activity was shown.
Claims (2)
상기와 같이 제조된 당침액 원액을 멸균되어진 물과 중량대비 1:1 비율로 혼합하여 최종 당침액을 제조하고,
상기 최종 당침액에 건조 도라지 절편을 부피비율로 2:1의 비율로 혼합하여 상기 건조 도라지 절편을 최종 당침액에 부유되지 않토록 완전하게 침지시킨 상태에서, 70℃에서 6시간 가열하여 1차 당침하고, 1차 당침 후 부유되지 않게 당침된 상태에서 12시간 실온 숙성 후, 70℃ 온도로 부유되지 않은 상태에서 6시간 가열하여 2차 당침을 진행하고.
상기 1,2차 당침 과정 이후에 실온에서 6시간 동안 건조하면서 도라지에 묻어 있는 당침액을 자연스럽게 흘려서 제거시키고,
그후 45℃ 온도에서 24시간 건조시킨후 12% 이하의 수분함량을 유지토록 한 상태에서 진공 포장토록 하는 호흡기 개선에 효과가 있는 도라지 당절편의 제조방법Each dried Cheonmundong and Hwangchil were finely chopped and extracted repeatedly with 10 times the weight of 50% ethanol at 70°C three times for 24 hours, filtered, concentrated, and freeze-dried to obtain each powdered extract, as described above. The obtained powdered Cheonmundong and Hwangchil were mixed in a ratio of 5:5 by weight to obtain a Hwangchil + Cheonmundong extract blend, and in this state, the total weight was set to 100% by weight, and 60% by weight of the Hwangchil + Cheonmundong extract blend and red ginseng powder extract were added. Prepare sugar needle solution by mixing 10% by weight and 30% by weight of honey,
The final sugar needle solution was prepared by mixing the sugar needle solution prepared as above with sterilized water in a 1:1 ratio by weight,
The dried bellflower slices were mixed in the final sugar steeping solution at a volume ratio of 2:1, the dried bellflower slices were completely immersed so that they did not float in the final sugar steeping solution, and then heated at 70°C for 6 hours to make the first sugar needle. After the first sugar needle, the sugar was aged at room temperature for 12 hours in a non-floating state, and then heated at 70°C for 6 hours in a non-floating state for the second sugar needle.
After the first and second sugar needle processes, the sugar needle liquid on the balloon flower is naturally drained and removed while drying at room temperature for 6 hours.
A method of manufacturing balloon flower segments that are effective in improving the respiratory system by drying them at 45°C for 24 hours and then vacuum-packing them while maintaining a moisture content of 12% or less.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190093547A KR102624473B1 (en) | 2019-07-31 | 2019-07-31 | A Manufacturing method of sliced bellflower sugared |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190093547A KR102624473B1 (en) | 2019-07-31 | 2019-07-31 | A Manufacturing method of sliced bellflower sugared |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20210015147A KR20210015147A (en) | 2021-02-10 |
KR102624473B1 true KR102624473B1 (en) | 2024-01-15 |
Family
ID=74560821
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020190093547A KR102624473B1 (en) | 2019-07-31 | 2019-07-31 | A Manufacturing method of sliced bellflower sugared |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102624473B1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101283775B1 (en) * | 2013-02-04 | 2013-07-08 | 재단법인 전라남도생물산업진흥재단 | Pharmaceuticlal composition for anti-tussive activity or discharge of phlegm activity comprising extracts of dendropanax morbifera |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101563802B1 (en) * | 2014-02-12 | 2015-10-27 | 김명신 | Bellflower preserved in honey made by adding the magnolia tea and manufacturing method for the same |
KR20170003153A (en) * | 2015-06-30 | 2017-01-09 | 이충렬 | A composition for the prevention and treatment of respiratory organ disease comprising the fractions of Asparagus cochinchinensis as an active ingredien |
-
2019
- 2019-07-31 KR KR1020190093547A patent/KR102624473B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101283775B1 (en) * | 2013-02-04 | 2013-07-08 | 재단법인 전라남도생물산업진흥재단 | Pharmaceuticlal composition for anti-tussive activity or discharge of phlegm activity comprising extracts of dendropanax morbifera |
Also Published As
Publication number | Publication date |
---|---|
KR20210015147A (en) | 2021-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang et al. | Emerging roles of Ganoderma lucidum in anti-aging | |
Chen et al. | Induction of mitochondrial-dependent apoptosis in T24 cells by a selenium (Se)-containing polysaccharide from Ginkgo biloba L. leaves | |
Chen et al. | Effect of lemon water soluble extract on hyperuricemia in a mouse model | |
Melicháčová et al. | Relation of total antiradical activity and total polyphenol content of sweet cherries (Prunus avium L.) and tart cherries (Prunus cerasus L.) | |
KR102127911B1 (en) | The composition of fermented beverage for immunity enhancement and method for production thereof | |
Xiong et al. | Polyphenols isolated from Acacia mearnsii bark with anti-inflammatory and carbolytic enzyme inhibitory activities | |
KR100854685B1 (en) | Production method of ginseng steamed red concentrated solution and ginseng steamed red concentrated solution produced by this method | |
Peng et al. | Anti-inflammatory effect of flavonoids from chestnut flowers in lipopolysaccharide-stimulated RAW 264.7 macrophages and acute lung injury in mice | |
US10058579B2 (en) | Dietary supplements containing extracts of cinnamon and methods of using same to promote enhanced sirtuin, cell and telomere integrity | |
KR102624473B1 (en) | A Manufacturing method of sliced bellflower sugared | |
KR101605057B1 (en) | Composition comprising fermented ginseng or red ginseng extract containing increased ginsenoside Rd for improving atopic dematitis | |
KR102005031B1 (en) | The Ginseng-Berry extract including alcoholic liver injury prevention functional ingredients and method for manufacturing it | |
WO2023216951A1 (en) | Anti-aging composition containing uridine acid, adenylic acid and yeast peptide and use thereof | |
KR102511861B1 (en) | Composition for strengthening muscle strength comprising a complex extract of Angelica keiskei and Morus alba leaves | |
Leem et al. | Extrusion process enhances the anti-inflammatory effect of Acanthopanax senticosus leaves | |
Thinkratok et al. | Inhibitory potential of the rambutan rind extract and tannin against alpha-amylase and alpha-glucosidase activities in vitro | |
Ban et al. | Effect of feeding type 2 diabetes mellitus rats with synbiotic yogurt sweetened with monk fruit extract on serum lipid levels and hepatic AMPK (5′ adenosine monophosphate-activated protein kinase) signaling pathway | |
KR102191409B1 (en) | Food compositions containing red ginseng and lactic acid fermentation broth and method for preparing the same | |
Zailan et al. | Evaluation of Phytochemical Composition, Antioxidant and anti-Diabetic Activities of Mitragyna speciosa Methanolic Extract (MSME). | |
US7226624B2 (en) | Synergistic compositions from yeast-modified aqueous extracts from almond hulls | |
KR20210092126A (en) | Sirtuin-1 activation agent and skin cosmetic for activating sirtuin 1 | |
KR100842054B1 (en) | Composition containing extracts of Glycyrrhizin Radix Praepara or compounds isolated therefrom for the Blood Glucose-Lowering effect | |
KR101095035B1 (en) | Composition for the prevention and treatment of obesity, hyperlipidemia and fatty liver comprising Zingerber officinale, Taraxacum platycarpum and Scutellaria baicalensis | |
JP2008214246A (en) | Age production inhibitor and method for producing the same | |
KR20210072543A (en) | Healthful composition comprising a jujube flesh extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |